Tenofovir

Tenofovir

Over a 14-year period, Gilead Sciences, Inc. ("Gilead") profited from exposing its patients to TDF-based medications by actively concealing and failing to bring to market safer, more effective TAF-based alternatives. Had Gilead acted reasonably under the circumstances in which it developed tenofovir as an antiretroviral treatment for HIV-1, it would have abandoned TDF in favor of TAF, thus reducing the risk of foreseeable and avoidable injuries like chronic kidney disease, renal failure, and bone mineral density disorders.

The Tenofovir Litigation Group aims to educate members and provide a forum to brainstorm ideas about how to most effectively represent clients negatively impacted by tenofovir. The Group provides member benefits such as access to pleadings, discovery, legal research, list servers, education programs, a medical literature database, and opportunities to share ideas in educational meetings.

The Tenofovir Litigation Group is sponsored by Epiq.

• Meetings: The group meets at AAJ Annual and Winter conventions.

• Membership: The group is limited to AAJ Regular, Life, Sustaining, and President’s Club members only.

• Annual Dues: The Litigation Group is complementary to members of the AAJ Pharmaceutical and Medical Device Section who can agree to the terms and conditions of membership in the Litigation Group's Affidavit. If you are not yet a member, you can join the Pharmaceutical and Medical Device Section here.

Cochairs 

Adam Gomez | Grant & Eisenhofer, PA, Wilmington, DE

Robert Jenner | Jenner Law, PC, Baltimore, MD